Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.67 |
| ▸ | TACR3 | P29371 | 1/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 3/20 | 0.47 |
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
| ▸ | ACACA | Q13085 | 2/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13871837 | 0.96 | TACR1 (0.62) | TACR1TACR3L3MBTL3L3MBTL1USP2 | |
| SCHEMBL13145004 | 0.95 | TACR1 (0.65) | TACR1TACR3USP2 | |
| SCHEMBL4817425 | 0.94 | TACR1 (0.66) | TACR1TACR3USP2 | |
| SCHEMBL4817431 | 0.94 | TACR1 (0.66) | TACR1TACR3USP2 | |
| SCHEMBL14017631 | 0.94 | TACR1 (0.66) | TACR1TACR3USP2 | |
| SCHEMBL13980837 | 0.92 | TACR1 (0.60) | TACR1TACR3L3MBTL3L3MBTL1USP2 | |
| SCHEMBL13871845 | 0.91 | TACR1 (0.58) | TACR1TACR3L3MBTL3L3MBTL1USP2 | |
| SCHEMBL13980681 | 0.91 | TACR1 (0.60) | TACR1TACR3L3MBTL3L3MBTL1USP2 | |
| SCHEMBL13871857 | 0.90 | TACR1 (0.58) | TACR1TACR3L3MBTL3L3MBTL1USP2 | |
| SCHEMBL13980743 | 0.90 | TACR1 (0.56) | TACR1TACR3USP2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | claimed |
| US-20060128721-A1 | Novel formulations of opioid-based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives | JANSSENS FRANS E | 2006-06-15 | — | — | US | claimed |
| EP-1635811-A2 | SUBSTITUTED 1, 4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVE COMBINED WITH AN OPIOID ANALGESIC AND THEIR USE FOR THE TREATMENT OF PAIN AND SIDE-EFFECTS ASSOCIATED WITH OPIOID-BASED TREATMENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-22 | — | — | EP | claimed |
| WO-2004110415-A2 | SUBSTITUTED 1, 4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVE COMBINED WITH AN OPIOID ANALGESIC AND THEIR USE FOR THE TREATMENT OF PAIN AND SIDE-EFFECTS ASSOCIATED WITH OPIOID-BASED TREATMENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-23 | — | — | WO | claimed |
| EP-1551804-B1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-24 | — | — | EP | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
| US-20060128721-A1 | Novel formulations of opioid-based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives | JANSSENS FRANS E | 2006-06-15 | — | — | US | disclosed |
| EP-1635811-A2 | SUBSTITUTED 1, 4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVE COMBINED WITH AN OPIOID ANALGESIC AND THEIR USE FOR THE TREATMENT OF PAIN AND SIDE-EFFECTS ASSOCIATED WITH OPIOID-BASED TREATMENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110415-A2 | SUBSTITUTED 1, 4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVE COMBINED WITH AN OPIOID ANALGESIC AND THEIR USE FOR THE TREATMENT OF PAIN AND SIDE-EFFECTS ASSOCIATED WITH OPIOID-BASED TREATMENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128721-A1 | Novel formulations of opioid-based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives | OPRK1, OPRL1, OPRM1 | TACR1 34/4885TACR3 666/4885L3MBTL3 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.